A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.

Shares of ImmunityBio Inc. grew as much as 18.8 percent at intraday trading before ending the day just up by 14.01 percent at ...

The commercial distribution of ANKTIVA commenced in May 2024, and the company believes it has the potential to become a ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...

ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

Jeremy Walsh is now heading up artificial intelligence and information technology in a newly created position at the FDA.